• Regen BioPharma Reports Success of NR2F6 Small Molecule Screening Program americanpharmaceuticalreview
    September 03, 2018
    Regen BioPharma has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently identified novel chemical compounds appear to inhibit NR2F6 and show potential for treating autoimmune diseases su
PharmaSources Customer Service